Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 5,572 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Degenerative Conditions, Neurologic Clear all

Conditions: Optic, Atrophy, Hereditary, Leber
Interventions: GS010, Sham Intravitreal Injection; Biological · Device
Lead sponsor: GenSight Biologics; Industry
Eligibility: 15 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania

Conditions: Facial Angiofibroma, Tuberous Sclerosis
Interventions: rapamycin, placebo; Drug
Lead sponsor: Dermatology Specialties Limited Partnership; Industry
Eligibility: 6 Years to 65 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Phoenix, Arizona • La Jolla, California • St. Petersburg, Florida + 3 more

Conditions: Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10, RFC1 Gene Mutation, Spinocerebellar Ataxia Type 27b, Healthy Participants
Interventions: Genetic Testing, Blood Collection, Magnetic Resonance Imaging (MRI) Scan, Assessments and Questionnaires, Cerebrospinal Fluid Collection; Genetic · Other
Lead sponsor: Lauren Moore; Other
Eligibility: 6 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2030
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Gainesville, Florida + 12 more

Conditions: ALS
Interventions: AMX0035; Drug
Lead sponsor: Amylyx Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Memory Disorders, Alzheimer Disease, Dementia, Cognitive Impairment, Frontotemporal Dementia
Interventions: COGNISION™ System; Device
Lead sponsor: Neuronetrix, Inc.; Industry
Eligibility: 60 Years to 90 Years
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 7
States / cities: West Palm Beach, Florida • Lexington, Kentucky • Louisville, Kentucky + 4 more

Conditions: Alzheimer's Disease
Interventions: E2212, placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Parkinson Disease (PD), Type 1 Gaucher Disease
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 40 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: ALS, Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, Motor Neuron Disease
Interventions: Tocilizumab, Placebo; Drug · Other
Lead sponsor: Barrow Neurological Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Phoenix, Arizona • Kansas City, Kansas • Boston, Massachusetts + 2 more

Conditions: Parkinson's Disease
Interventions: Deep Brain Stimulation; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 18 more

Conditions: Anxiety, Anxiety Disorders and Symptoms, Caregiver Burnout
Interventions: ACT Acceptance and Commitment Therapy; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Low Vision
Interventions: Virtual bioptic magnification with large field of view, Full field magnification with small field of view; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 14 Years to 100 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Spinal and Bulbar Muscular Atrophy, Kennedy's Disease
Interventions: AJ201, Placebo; Drug
Lead sponsor: AnnJi Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Orange, California • Palo Alto, California • Jacksonville, Florida + 3 more

Conditions: Alzheimer's Disease Related Dementia, Alzheimer Disease
Interventions: Emergency Care Redesign (ECR), Nurse-led Telephonic Care (NLTC), Community Paramedic-led Transitions Intervention (CPTI); Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 66 Years and older
Enrollment: 19,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Polypharmacy, Alzheimer Disease and Related Dementias
Interventions: Pharmacist-led deprescribing intervention; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Aurora, Colorado • Baltimore, Maryland

Conditions: Amyloidogenic Transthyretin (ATTR) Amyloidosis, Cardiac Amyloidosis
Interventions: Evuzamitide; Drug
Lead sponsor: Lorena Saelices; Other
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Dallas, Texas

Conditions: Parkinson Disease
Interventions: Allopregnanolone; Drug
Lead sponsor: Roberta Brinton; Other
Eligibility: 40 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Amyotrophic Lateral Sclerosis (ALS), Motor Neuron Disease (MND), Primary Lateral Sclerosis (PLS)
Interventions: Education about treatment options, Dietary Supplements: Vitamins, Minerals, Herbs, etc., Meditation, Prayer, Talk Therapy, Affirmations, Journaling, etc., Diet, various diets will be observed, Exercise, physical therapy, occupational therapy, speech therapy, sauna, EMS, massage and other therapies, ALS medications and other medications, Physical and emotional support; Other · Dietary Supplement · Behavioral + 1 more
Lead sponsor: Healing Advocates Registry and Ministry; Other
Eligibility: 18 Years to 110 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: Park City, Utah

Conditions: Neurofibromatosis Type 2
Interventions: Doxycycline Injection [Doxy]; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 8 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson Disease
Interventions: DBS Programming; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Muscular Atrophy, Spinal
Interventions: Placebo, Risdiplam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Palo Alto, California • New York, New York

Conditions: Alzheimer's Dementia
Interventions: Resonator; Device
Lead sponsor: pico-tesla Magnetic Therapies, LLC; Industry
Eligibility: 55 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: Regular Insulin, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 55 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Parkinson's Disease
Interventions: Levodopa, Zolpidem first dose, Zolpidem second dose, sugar pill; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 30 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation

Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex

Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.

A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects

Parkinson's Disease in Type 1 Gaucher Disease

A Trial of Tocilizumab in ALS Subjects

Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease

Possible Therapy by Phone for Caregivers

Design and Clinical Evaluation of a Smartphone-based Low Vision Enhancement System

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients

ED-LEAD: Emergency Departments Leading the Transformation of Alzheimer's and Dementia Care

Aligning Medications With What Matters Most

PET Imaging Study Using Evuzamitide to Detect Cardiac Amyloidosis in Patients With Inconclusive Nuclear Scans and Elevated TAD1 Levels

Allopregnanolone as a Regenerative Treatment for Parkinson's Disease

Genetic Analysis of Parkinson's Disease

Healing ALS Registry Observational Study (HAROS)

Doxycycline in Cutaneous Schwannoma (NF2)

Advancing Pre-operative Targeting for Deep Brain Stimulation in the Globus Pallidus Internus

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants

Safety and Efficacy Study of Magnetic Fields to Treat Alzheimer's Disease

SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)

Use of Zolpidem in Parkinson's Disease